 |
Tokyo, Japan, Dec. 09, 2005 - (JCN Newswire) - Shionogi & Co., Ltd. (TSE: 4507) today announced the Japan launch of "Avelox(R) Tablet 400mg (moxifloxacin hydrochloride), a new quinolone antibacterial licensed from Bayer Yakuhin, Ltd. (Head Office: Osaka) Avelox(R) Tablet, a respiratory quinolone, was developed by Bayer HealthCare AG. It has demonstrated an excellent antibacterial effect on all the major bacterial causes of respiratory tract infections. First approved in 1999 in Europe and the United States, this agent has been used to date to treat more than 40 million patients in 85 countries over its full range of indications.
Bayer Yakuhin and Shionogi reached an agreement in October 2003, under which Bayer Yakuhin granted exclusive Japanese marketing rights for Avelox(R) Tablet to Shionogi. In accordance with the agreement, Bayer Yakuhin acquired import approval on October 11, 2005 and upon obtaining National Health Insurance price listing today, Shionogi immediately launched the product and commenced domestic marketing on an exclusive
basis.
In order to facilitate the rapid penetration of Avelox(R) Tablet into the Japanese market, both companies will continue to work closely together in the areas of marketing and postmarketing surveillance.
Avelox(R) Tablet 400mg Product Summary
Product name: Avelox(R) Tablet 400mg
Generic name: Moxifloxacin hydrochloride
Acquisition of import approval: October 11, 2005
NHI drug price listing: December 9, 2005
Date of market launch: December 9, 2005
Main characteristics: Expected to have significant clinical efficacy as a respiratory quinolone because of its excellent antibacterial effect on all the major bacterial causes of respiratory tract infections and good migration to all tissues in the respiratory tract.
NHI drug price: 544.40 yen for one 400mg tablet (Daily drug cost of 544.40 yen)
About Bayer HealthCare AG
Bayer HealthCare AG, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the health care and medical products industry. In 2004, the Bayer HealthCare subgroup generated sales amounting to some 8.5 billion Euro. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Bayer HealthCare employed 35,300 people worldwide in 2004. Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating disease. Visit: www.bayerhealthcare.com and http://www.cardio.bayer.com
About Bayer Yakuhin Ltd. (Osaka, Japan)
Bayer Yakuhin Ltd. is in charge of Japanese health care markets as a part of the global operations of Bayer HealthCare AG. The company employs 1,500 staff and develops pharmaceutical, consumer care and biological products. Bayer Yakuhin has set itself the challenge to build a customer focused health care company that significantly contributes to human health by encouraging innovation and creativity. Home Page: http://www.bayer.co.jp/byl/index.html
About Shionogi and Co., Ltd.
Shionogi & Co., Ltd, established in 1887 and was incorporated in 1919, is a major research-driven Japanese pharmaceutical manufacturer. The company's primary businesses are research and development, manufacturing, marketing, and import and export sales of pharmaceutical and diagnostics products. Shionogi follows a basic policy of continually providing the superior medicines essential to people's health. For more details, please visit http://www.shionogi.co.jp
For further information, please visit the Shionogi and Co., Ltd. home page at: www.shionogi.co.jp/index_e.html
Contact
Bayer Yakuhin, Ltd.
Communications Department
Fujita Shimazaki
TEL: + 81-6-6398-1036
FAX: + 81-6-6398-1033
Shionogi & Co., Ltd.,
Public Relations Unit
Osaka TEL: +81-6-6209-7885
FAX: +81-6-6229-9596
Tokyo TEL: +81-3-3406-8164
FAX: +81-3-3406-8099
|
